The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and neuropathic pain. These approvals are responsible for the increasing importance of anticonvulsants in the management of various pain indications. The overall market for anticonvulsants is highly genericized; however, the market for anticonvulsants for pain management application is dominated by Lyrica, the only branded pharmaceutical among the currently marketed drugs.
Read Report Overview - https://www.transparencymarketresearch.com/anticonvulsants-drug-market.html
Of the major anticonvulsant drugs currently marketed, Lyrica (pregabalin), Neurontin (gabapentin), Topamax (topiramate), Depakote (divalproex), and Carbatrol/Tegretol (carbamazepine) are indicated for management of various types of pain. In 2012, Lyrica registered sales of US$ 5,111 Mn, of which 74% constituted revenue from its pain management indication. Since all the other molecules are generic and have negligible contribution in the pain management application, the market will be driven and dominated by the sales of existing blockbuster drug Lyrica, which constituted 73.4% share of the total market in 2011. The drug was initially set to lose its patent exclusivity in 2015, which would have negatively impacted the market rendering it completely generic. However, Pfizer has obtained market exclusivity for the drug and its use in pain management through to 2018, and is therefore expected to maintain its leadership position.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22973
Rising prevalence of epilepsy is the key driver of the anticonsultants drug market. Anticonvulsants drug is not only consumed in case of epileptic seizures, but also for pain management in migraine, and fibromyalgia. This boosts the anticonvulsants drug market. Availability of alternative options for pain management acts as a major restraint of the market. Other pain management methods include the use of medical devices such as analgesic pumps and minimally invasive procedures such as denervation or rhizotomy. Pain management implants and devices such as neuromodulators are gaining market acceptance among medical professionals, while acupuncture and acupressure are world-renowned pain relief techniques along with physiotherapy that people adopt. Other devices included in pain relief are transcutaneous electrical nerve stimulation (TENS) that delivers mild shocks to nerves in order to block pain messages to the brain. Hence, competition in the market from other improved pain management methods, devices, and other drugs can also hamper the anticonvulsants drug market. The anticonvulsants drug market has been segmented based on therapeutic class, disease indication, formulation, distribution channel, and region.
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=22973
In terms of therapeutic class, the anticonvulsants drug market has been segmented into:
· Barbiturates
o Phenobarbital
o Primidone
· Benzodiazepines
o Clobazam
o Clonazepam
o Diazepam
· Hydantoins
o Ethotoin
o Phenytoin
· Succinimides
o Ethosuximide
o Methsuximide
· Others
Pre Book X Anticonvulsants Drug Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=22973<ype=S
Based on disease indication, the anticonvulsants drug market has been segmented into:
· Epilepsy
· Pain Management
o Migraine
o Neuropathic pain
o Fibromyalgia
In terms of formulation, the anticonvulsants drug market has been segmented into:
· Enteral
o Tablets
o Capsules
· Parenteral
o Liquid
o Lyophilized
· Topical
o Rectal Gels
o Creams
o Others
Request TOC of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22973
Based on distribution channel, the anticonvulsants drug market has been segmented into:
· Hospital Pharmacies
· Online Pharmacies
· Retail Pharmacies
· Drug Stores
In terms of region, the anticonvulsants drug market has been classified into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America. Key players in the anticonvulsant drug market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals International, Inc., Sanofi, UCB, Shire plc., and Astrazeneca plc.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
